Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells.
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007694:Killer Cells, Natural; D008222:Lymphokines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*
D007376:Interleukin-2; D008222:Lymphokines